Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054912 · ClinicalTrials.gov registry record · Phase 1
An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer
A Phase 1 study of Colorectal Neoplasms and Colonic Neoplasms, sponsored by Epimmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 9
- Study locations
NCT00054912: Completed Phase 1 study of Colorectal Neoplasms and Colonic Neoplasms, sponsored by Epimmune.
NCT00054912 is a Phase 1 study of Colorectal Neoplasms and Colonic Neoplasms that has completed, run by Epimmune. The registered enrollment target is 18 participants, below the 576-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (97% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00054912, a Phase 1 study of Colorectal Neoplasms and Colonic Neoplasms, has completed, sponsored by Epimmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 9
- Study locations
Study Summary
EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Colon Cancer.
Conditions Studied
Interventions
- BIOLOGICAL EP2101
Study Locations (9)
California
- University of Southern California School of Medicine - Los Angeles
- University of California, San Diego - San Diego
Texas
- Mary Crowley Medical Research Center - Dallas
- Tyler Cancer Center - Tyler
Washington
- University of Washington - Seattle
- Cancer Care Northwest - Spokane
Florida
- Cancer Centers of Florida - Orlando
New York
- New York Oncology Hematology - Albany
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2003-02 |
| Phase | Phase 1 |
What the finished NCT00054912 record still lists
NCT00054912 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 576-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Colorectal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which EP2101 is the first listed.
NCT00054912 lists 9 locations in 6 states (California, Texas, Washington).
Frequently Asked Questions
What is clinical trial NCT00054912 about?
NCT00054912 is a clinical study titled "An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer". EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer. This study will test the safety and measure the level of immune stimulating ...
What is the current status of trial NCT00054912?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2003-02.
What conditions does trial NCT00054912 study?
This clinical trial studies the following conditions: Colorectal Neoplasms, Colonic Neoplasms.
What interventions are being tested in trial NCT00054912?
The interventions under investigation include: EP2101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00054912?
This trial is sponsored by Epimmune, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00054912 being conducted?
This trial has 9 study locations across California, Florida, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00054912's enrollment target sits among peer trials
18 55th of 54 the lowest of 54 other Colorectal Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia